Literature DB >> 26058239

Prevalence and risk factors for developing oral allergy syndrome in adult patients with seasonal allergic rhinitis.

Nada Ivičević, Željka Roje, Zlatko Kljajić, Lovro Bojić, Goran Kardum, Lada Omero, Goran Račić.   

Abstract

The aim of this study was to assess the prevalence of oral allergy syndrome (OAS) in patients with seasonal allergic rhinitis (SAR) and the possible risk factors for its development. This cross-sectional study was conducted in primary care offices in the Split-Dalmatia County during the period from March 1 to September 30, 2012. Data sources were medical history with confirmation of SAR (positive skin-prick test to seasonal inhalant allergens: grass, tree and weed pollens), anthropometric patient data (age, sex, weight and height), and a questionnaire in which patients evaluated their nasal and ocular symptoms, comorbidities and lifestyle. The χ2-test, Pearson χ2-test, Spearman's rho correlation coefficient and Kolmogorov-Smirnov test were used on statistical analysis. The prevalence of OAS was 45.7%. The risk factors for OAS development were diabetes (p < 0.001), severity of nasal symptoms (p < 0.05) and severity of ocular symptoms (p < 0.001). In conclusion, the prevalence of OAS in the Split-Dalmatia County is very high. The risks factors for OAS in patients with SAR are diabetes and severity of nasal and ocular symptoms.

Entities:  

Mesh:

Year:  2015        PMID: 26058239

Source DB:  PubMed          Journal:  Acta Clin Croat        ISSN: 0353-9466            Impact factor:   0.780


  2 in total

1.  Otolaryngologists Practice Pattern on Oral Allergy Syndrome.

Authors:  Yunjia Zhang Md; Haidy Marzouk Md
Journal:  Allergy Rhinol (Providence)       Date:  2021-05-28

2.  Clinical Characteristics of Oral Allergy Syndrome in Children with Atopic Dermatitis and Birch Sensitization: a Single Center Study.

Authors:  Kang-In Kim; Bomi Lee; Taek Ki Min; Jeongho Lee; Bok Yang Pyun; You Hoon Jeon
Journal:  J Korean Med Sci       Date:  2019-01-02       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.